BRF2 and cancer: Additionally, Brf2 overexpression is observed in several forms of cancers and correlates with poor patient survival rates, implicating Brf2 as a general oncogene, a prognosis marker, and a target for new anticancer therapies (Cabarcas and Schramm, 2011, Lu et al., 2013, Lu et al., 2014).